TherapeuticsMD (TXMD) Misses Q3 EPS by 1c

TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $24.5 million versus the consensus estimate of $25.87 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• The LGL Group (LGL) Misses Q2 EPS by 8c
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance